Update on pharmacogenetics in epilepsy: a brief review

被引：57
作者：
Szoeke, CEI [1 ]
Newton, M
Wood, JM
Goldstein, D
Berkovic, SF
OBrien, TJ
Sheffield, LJ
机构：
[1] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[2] Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic, Australia
[3] Austin Hlth, Dept Neurol, Melbourne, Vic, Australia
[4] Mental Hlth Res Inst, Dept Pharmacogenom, Melbourne, Vic, Australia
[5] UCL, London, England
[6] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia
来源：
LANCET NEUROLOGY | 2006年 / 5卷 / 02期
关键词：
D O I：
10.1016/S1474-4422(06)70352-0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Recent developments in the pharmacogenetics of antiepileptic drugs provide new prospects for predicting the efficacy of treatment and potential side-effects. Epilepsy is a common, serious, and treatable neurological disorder, yet current treatment is limited by high rates of adverse drug reactions and lack of complete seizure control in a significant proportion of patients. The disorder is especially suitable for pharmacogenetic investigation because treatment response can be quantified and side-effects can be assessed with validated measures. Additionally, there is substantial knowledge of the pharmacodynamics and kinetics of antiepileptic drugs, and some candidate genes implicated in the disorder have been identified. However, recent studies of the association of particular genes and their genetic variants with seizure control and adverse drug reactions have not provided unifying conclusions. This article reviews the published work and summarises the state of research in this area. Future directions for research and the application of this technology to the clinical practice of individualising treatment for epilepsy are discussed.
引用
收藏
页码：189 / 196
页数：8
相关论文
共 101 条
[51]   Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy [J].
Lazarowski, A ;
Massaro, M ;
Schteinschnaider, A ;
Intruvini, S ;
Sevlever, G ;
Rabinowicz, A .
THERAPEUTIC DRUG MONITORING, 2004, 26 (01) :44-46
[52]   Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy [J].
Lazarowski, A ;
Lubieniecki, F ;
Camarero, S ;
Pomata, H ;
Bartuluchi, M ;
Sevlever, G ;
Taratuto, AL .
PEDIATRIC NEUROLOGY, 2004, 30 (02) :102-106
[53]   Neuronal and glial expression of the multidrug resistance gene product in an experimental epilepsy model [J].
Lazarowski, A ;
Ramos, AJ ;
García-Rivello, H ;
Brusco, A ;
Girardi, E .
CELLULAR AND MOLECULAR NEUROBIOLOGY, 2004, 24 (01) :77-85
[54]   Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy [J].
Lazarowski, A ;
Sevlever, G ;
Taratuto, A ;
Massaro, M ;
Rabinowicz, A .
PEDIATRIC NEUROLOGY, 1999, 21 (04) :731-734
[55]   Role of multidrug transporters in pharmacoresistance to antiepileptic drugs [J].
Löscher, W ;
Potschka, H .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (01) :7-14
[56]   Current status and future directions in the pharmacotherapy of epilepsy [J].
Löscher, W .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (03) :113-118
[57]   The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics [J].
Mamiya, K ;
Ieiri, I ;
Shimamoto, J ;
Yukawa, E ;
Imai, J ;
Ninomiya, H ;
Yamada, H ;
Otsubo, K ;
Higuchi, S ;
Tashiro, N .
EPILEPSIA, 1998, 39 (12) :1317-1323
[58]   CYP2C19 polymorphism effect on phenobarbitone - Pharmacokineties in Japanese patients with epilepsy: analysis by population pharmacokinetics [J].
Mamiya, K ;
Hadama, A ;
Yukawa, E ;
Ieiri, I ;
Otsubo, K ;
Ninomiya, H ;
Tashiro, N ;
Higuchi, S .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 55 (11-12) :821-825
[59]   Prognosis for total control of complex partial and secondarily generalized tonic clonic seizures [J].
Mattson, RH ;
Cramer, JA ;
Collins, JF ;
Browne, TR ;
Crill, WE ;
Homan, RW ;
Carter, GS ;
Mayersdorf, A ;
Davenport, J ;
Lubozynski, MF ;
Williamson, PD ;
Ebersole, JS ;
Scheyer, RD ;
McCutchen, CB ;
Mamdani, MB ;
Ramsay, RE ;
Rowan, AJ ;
Salinsky, M ;
McNamara, JO ;
Shin, C ;
Smith, DB ;
Treiman, DM ;
DelgadoEscueta, AV ;
Rosenthal, NP ;
Warner, JJ ;
Wilder, BJ .
NEUROLOGY, 1996, 47 (01) :68-76
[60]   Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy [J].
Odani, A ;
Hashimoto, Y ;
Otsuki, Y ;
Uwai, Y ;
Hattori, H ;
Furusho, K ;
Inui, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (03) :287-292
12345678910